Status:
COMPLETED
Iressa Case Control Study in Japan
Lead Sponsor:
AstraZeneca
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
Brief Summary
The purposes of this study are: * To estimate the relative risk of ILD in advanced/recurrence NSCLC patients treated with gefitinib as compared to other chemotherapy treatment, and to assess the risk...
Eligibility Criteria
Inclusion
- Advanced/recurrence NSCLC patients who have had one or more chemotherapy regimens.
- Patients who are to be treated with gefitinib or chemotherapy
- Cohort: All advanced/recurrence NSCLC patients participating in this post-marketing clinical study
Exclusion
- Patients judged by the investigator(s) to have ILD (provisional cases) among those registered in the cohort OR Randomly selected patients without ILD (controls) for each provisional case
- Case-control study: Patients enrolled in the case-control study; all consenting patients with ILD as cases and approximately 4 times as many consenting patients without ILD as controls randomly selected from the cohort
Key Trial Info
Start Date :
November 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2006
Estimated Enrollment :
6000 Patients enrolled
Trial Details
Trial ID
NCT00252759
Start Date
November 1 2003
End Date
February 1 2006
Last Update
January 28 2011
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Nagoya, Aichi-ken, Japan
2
Research Site
Okazaki, Aichi-ken, Japan
3
Research Site
Toyoake, Aichi-ken, Japan
4
Research Site
Imba-gun, Chiba, Japan